BIRC5 and pulmonary arterial hypertension: McMurtry et. al. (McMurtry et al., 2005) also reported that gene therapy with a phosphorylation deficient survivin mutant lowered pulmonary vascular resistance, right ventricular hypertrophy and pulmonary artery medial hypertrophy, and prolonged the survival time in MCT-induced PAH rats.